Imagine a high-tech camera system that acts like a super-powered magnifying glass for your skin. Instead of a doctor checking every mole one by one, this robot scans your entire body in a few minutes. It then uses smart software to spot any new or changing spots that might be dangerous, acting like an early warning system for skin cancer.
Dermatologists struggle to perform comprehensive full-body skin checks efficiently, often missing small changes in moles or performing too many unnecessary biopsies.
A robotic high-resolution imaging system and AI software that generates 3D human avatars and flags modified moles.
If you are a private clinic dealing with long patient wait times and manual screening errors — this project developed a robotic imaging system that performs full-body scans in less than 3 minutes. This allows for faster patient throughput and more accurate triage.
If you are a hospital dealing with high costs of unnecessary biopsies — this project developed AI triage assistance to flag concerning lesions. This reduces the number of invasive procedures and optimizes medical staff time.
If you are a payer dealing with the high cost of late-stage cancer treatments — this project developed a high-resolution scanning tool for early detection. This enables faster access to treatment and lowers long-term care costs.
Based on available project data, the specific commercial price or cost of the system is not disclosed.
Yes, the project objective is to make this screening accessible to everyone, everywhere, using a system that completes scans in less than 3 minutes.
The solution utilizes patented technologies in 3D human avatar generation and robotic control, though specific licensing terms are not listed.
It integrates hardware and software for robotic planning, imaging, and secure storage to provide a seamless experience for physicians and patients.
The project period ran from 2022-07-01 to 2024-12-31, indicating the development phase is now closed.
The project is led by a single French SME, SQUAREMIND, which acted as the sole coordinator and partner. This 100% industry-led structure suggests a strong focus on commercial viability and rapid development rather than academic research.
Contact SQUAREMIND in France for commercial inquiries regarding the SWAN system.
Contact us to facilitate a partnership with SQUAREMIND for clinical deployment.
